Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD1801 Single Ascending Dose Study in Healthy Subjects
NCT03099603Phase 1Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Mar 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of berberine ursodeoxycholate in Primary Sclerosing Cholangitis (PSC) (4 arms), sponsored by HighTide Therapeutics, Inc. Primary endpoint: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) at 30 days. Started Mar 2017; status: completed.
02
Drugs
berberine ursodeoxycholate
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03099603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099603.